Abbvie (ABBV) Valuation Rose While First Financial Has Lowered Position by $869,616; Centerbridge Partners LP Holding in Ally Finl (ALLY) Decreased as Market Valuation Declined

February 23, 2018 - By Louis Casey

Mark T. Gallogly decreased its stake in Ally Finl Inc (ALLY) by 88.12% based on its latest 2017Q3 regulatory filing with the SEC. Centerbridge Partners Lp sold 1.66M shares as the company’s stock declined 19.04% while stock markets rallied. The hedge fund run by Mark T. Gallogly held 224,186 shares of the consumer services company at the end of 2017Q3, valued at $5.44 million, down from 1.89M at the end of the previous reported quarter. Centerbridge Partners Lp who had been investing in Ally Finl Inc for a number of months, seems to be less bullish one the $12.19 billion market cap company. The stock decreased 1.83% or $0.52 during the last trading session, reaching $27.89. About 1.89M shares traded. Ally Financial Inc. (NYSE:ALLY) has risen 12.72% since February 23, 2017 and is uptrending. It has underperformed by 3.98% the S&P500.

First Financial Corp decreased its stake in Abbvie Inc (ABBV) by 42% based on its latest 2017Q3 regulatory filing with the SEC. First Financial Corp sold 9,882 shares as the company’s stock rose 6.17% with the market. The institutional investor held 13,644 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $1.21 million, down from 23,526 at the end of the previous reported quarter. First Financial Corp who had been investing in Abbvie Inc for a number of months, seems to be less bullish one the $186.68 billion market cap company. The stock decreased 0.30% or $0.35 during the last trading session, reaching $117.56. About 5.19 million shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since February 23, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.




Investors sentiment decreased to 0.85 in Q3 2017. Its down 0.15, from 1 in 2017Q2. It dropped, as 55 investors sold ABBV shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. Gamco Et Al accumulated 0.01% or 18,848 shares. Vaughan David Invests Il invested 0.1% in AbbVie Inc. (NYSE:ABBV). Jensen Investment invested in 28,770 shares or 0.03% of the stock. South State Corporation holds 0.14% or 13,847 shares in its portfolio. Aspiriant Limited Liability Company reported 4,262 shares. Busey holds 0.3% or 28,046 shares. Lawson Kroeker Investment Mgmt Incorporated Ne reported 4,546 shares. Bartlett And Limited Co holds 0.5% in AbbVie Inc. (NYSE:ABBV) or 135,442 shares. State Treasurer State Of Michigan holds 0.49% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 686,503 shares. State Of New Jersey Common Pension Fund D holds 0.72% in AbbVie Inc. (NYSE:ABBV) or 2.02M shares. Independence Trust invested in 26,133 shares or 2.65% of the stock. Eastern Natl Bank owns 62,978 shares. Bkd Wealth Advsrs Limited Co has 14,759 shares for 0.14% of their portfolio. Profund Ltd invested 2.52% of its portfolio in AbbVie Inc. (NYSE:ABBV). Exxonmobil Invest Tx invested in 291,105 shares or 0.65% of the stock.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 9 Hold. Therefore 48% are positive. Abbvie Inc had 78 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Neutral” rating by UBS on Monday, September 25. Morgan Stanley upgraded the shares of ABBV in report on Monday, November 2 to “Overweight” rating. The company was maintained on Friday, October 13 by UBS. The stock of AbbVie Inc. (NYSE:ABBV) has “Outperform” rating given on Monday, October 2 by Leerink Swann. The rating was maintained by SunTrust with “Buy” on Monday, October 16. The firm has “Buy” rating given on Friday, January 26 by Cowen & Co. The rating was downgraded by Morgan Stanley on Wednesday, June 8 to “Equal-Weight”. Citigroup upgraded AbbVie Inc. (NYSE:ABBV) on Monday, September 28 to “” rating. Cowen & Co maintained AbbVie Inc. (NYSE:ABBV) on Monday, November 20 with “Buy” rating. The stock has “Buy” rating by Jefferies on Monday, June 26.

Since September 11, 2017, it had 0 insider purchases, and 6 sales for $25.71 million activity. Shares for $705,655 were sold by SALEKI-GERHARDT AZITA on Monday, September 11. Schumacher Laura J also sold $14.07 million worth of AbbVie Inc. (NYSE:ABBV) on Thursday, December 14. RICHMOND TIMOTHY J. sold $8.57M worth of stock or 87,040 shares. Gosebruch Henry O sold $1.66M worth of stock.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on April, 26. They expect $1.78 earnings per share, up 39.06% or $0.50 from last year’s $1.28 per share. ABBV’s profit will be $2.83B for 16.51 P/E if the $1.78 EPS becomes a reality. After $1.48 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 20.27% EPS growth.

Analysts await Ally Financial Inc. (NYSE:ALLY) to report earnings on April, 26. They expect $0.68 EPS, up 41.67% or $0.20 from last year’s $0.48 per share. ALLY’s profit will be $297.19 million for 10.25 P/E if the $0.68 EPS becomes a reality. After $0.70 actual EPS reported by Ally Financial Inc. for the previous quarter, Wall Street now forecasts -2.86% negative EPS growth.

Among 23 analysts covering Ally Financial (NYSE:ALLY), 16 have Buy rating, 1 Sell and 6 Hold. Therefore 70% are positive. Ally Financial had 61 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was downgraded by J.P. Morgan to “Hold” on Friday, January 12. Sandler O’Neill maintained it with “Hold” rating and $32.0 target in Monday, January 22 report. The company was maintained on Thursday, October 26 by BMO Capital Markets. The stock of Ally Financial Inc. (NYSE:ALLY) has “Buy” rating given on Wednesday, October 25 by BTIG Research. The firm has “Buy” rating given on Wednesday, January 10 by Jefferies. The stock of Ally Financial Inc. (NYSE:ALLY) has “Overweight” rating given on Thursday, October 26 by Morgan Stanley. On Thursday, January 4 the stock rating was maintained by Susquehanna with “Buy”. The company was maintained on Thursday, July 27 by Piper Jaffray. As per Tuesday, January 3, the company rating was maintained by Barclays Capital. The rating was maintained by Wood on Friday, April 7 with “Buy”.

Centerbridge Partners Lp, which manages about $20.91 billion and $858.75 million US Long portfolio, upped its stake in Ambac Finl Group Inc (NASDAQ:AMBC) by 771,562 shares to 787,851 shares, valued at $13.60 million in 2017Q3, according to the filing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts